Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ERIS – EGFR-Mutated Lung Cancer Randomized Study
2021-003755-41Phase 2Active
- Sponsor
- Region Skåne
- Start
- Aug 2021
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in EGFR-mutated non-small cell lung cancer comparing Osimertinib arm, Afatinib arm and Dacomitinib arm (3 arms). Primary endpoint: Primary biomarker identification. Started Aug 2021; status: active.
02
Drugs
03
Conditions
EGFR-mutated non-small cell lung cancer
Beyond the preview
Go deeper on 2021-003755-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003755-41.